|
1
|
Hirsch FR, Kerr KM, Bunn PA, Kim ES, Obasaju C, Pérol M, Bonomi P, Bradley JD, Gandara D, Jett JR, Langer CJ, Natale RB, Novello S, Paz-Ares L, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Stinchcombe TE, Vansteenkiste JF, Wakelee H, Thatcher N. Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. Clin Lung Cancer 2018; 19:331-339. [PMID: 29773328 DOI: 10.1016/j.cllc.2018.03.014] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2018] [Revised: 03/12/2018] [Accepted: 03/13/2018] [Indexed: 12/18/2022]
Abstract
Patients with non-small-cell lung cancer, including squamous-cell lung cancer (SqCLC), typically present at an advanced stage. The current treatment landscape, which includes chemotherapy, radiotherapy, surgery, immunotherapy, and targeted agents, is rapidly evolving, including for patients with SqCLC. Prompt molecular and immune biomarker testing can serve to guide optimal treatment choices, and immune biomarker testing is becoming more important for this patient population. In this review we provide an overview of current and emerging practices and technologies for molecular and immune biomarker testing in advanced non-small-cell lung cancer, with a focus on SqCLC.
Collapse
Affiliation(s)
- Fred R Hirsch
- Division of Medical Oncology, University of Colorado Cancer Center, Aurora, CO.
| | - Keith M Kerr
- Department of Pathology, University of Aberdeen School of Medicine and Aberdeen Royal Infirmary, Aberdeen, Scotland
| | - Paul A Bunn
- Division of Medical Oncology, University of Colorado Cancer Center, Aurora, CO
| | - Edward S Kim
- Levine Cancer Institute, Atrium Health, Charlotte, NC
| | | | - Maurice Pérol
- Department of Medical Oncology, Centre Léon Bérard, Lyon, France
| | - Philip Bonomi
- Department of Hematology and Oncology, Rush University Medical Center, Chicago, IL
| | - Jeffrey D Bradley
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO
| | - David Gandara
- Department of Hematology and Oncology, UC Davis Comprehensive Cancer Center, Sacramento, CA
| | - James R Jett
- Department of Oncology, formerly of National Jewish Health, Denver, CO
| | - Corey J Langer
- Department of Thoracic Oncology, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA
| | - Ronald B Natale
- Cedars-Sinai Comprehensive Cancer Center, West Hollywood, CA
| | - Silvia Novello
- Department of Oncology, University of Turin, Turin, Italy
| | - Luis Paz-Ares
- Department of Medical Oncology, Hospital Universitario Doce de Octubre, Universidad Complutense, CIBERONC and CNIO, Madrid, Spain
| | - Suresh S Ramalingam
- Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA
| | - Martin Reck
- Lung Clinic Grosshansdorf, Airway Research Center North, Member of the German Center for Lung Research, Grosshansdorf, Germany
| | | | - Egbert F Smit
- Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, The Netherlands
| | | | | | | | - Johan F Vansteenkiste
- Respiratory Oncology Unit, Department of Respiratory Medicine, University Hospital KU Leuven, Leuven, Belgium
| | - Heather Wakelee
- Department of Medicine (Oncology), Stanford Cancer Institute and Stanford University School of Medicine, Stanford, CA
| | - Nick Thatcher
- Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom
| |
Collapse
|
|
2
|
Morabito A. Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the 'panacea' for all patients? BMC Med 2018; 16:24. [PMID: 29448944 PMCID: PMC5815183 DOI: 10.1186/s12916-018-1011-0] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/02/2018] [Accepted: 01/22/2018] [Indexed: 12/12/2022] Open
Abstract
The therapeutic approach for the second-line treatment of patients with advanced non-small cell lung cancer (NSCLC) without actionable mutations has been revolutionized by the recent approval of new effective drugs with various mechanisms of action, including nintedanib, ramucirumab, nivolumab, pembrolizumab, atezolizumab, and afatinib. The recent network meta-analysis of Créquit et al. (BMC Medicine, 15:193, 2017) compared the effectiveness and tolerability of the second-line treatments for advanced NSCLC with wild-type or unknown status for EGFR. The authors found that immunotherapy might be more efficacious than the currently recommended treatments. However, their meta-analysis does not take into account the role of predictive biomarkers - this is indeed a crucial point in the decision-making process considering that only a fraction of advanced NSCLC patients might derive a long-term benefit from second-line immunotherapy. The identification of molecular biomarkers that can predict a response to immune checkpoints, angiogenesis, and EGFR inhibitors remains an important goal of clinical research in order to maximize the benefit of these agents and to aid clinicians in the decision-making process.Please see related article: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-017-0954-x.
Collapse
Affiliation(s)
- Alessandro Morabito
- The Medical Oncology Unit, Thoracic-Pulmonary Department, Istituto Nazionale Tumori, "Fondazione G. Pascale" - IRCCS, Via Mariano Semola, 80131, Naples, Italy.
| |
Collapse
|